ArticleHealth science reports2026
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost-effectiveness. Biosimilars-biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including inflammatory bowel disease, juvenile idiopathic arthritis, psoriasis, asthma, lupus nephritis, and growth hormone deficiencies. Despite regulatory, clinical, and societal challenges, current data suggest biosimilars demonstrate comparable safety, efficacy, and immunogenicity profiles to their originator products. The review consolidates findings from recent clinical trials, real-world data, and regulatory landscapes across the US and EU, emphasizing the growing role of biosimilars in pediatric pharmacotherapy. It also explores future directions in biosimilar development, highlighting the need for improved pediatric-specific research, regulatory harmonization, and stakeholder education to ensure wider adoption and optimized outcomes in children. Method: A structured literature search of PubMed, Scopus, Web of Science, and Google Scholar (2003-March 2026) identified English-language studies on pediatric biosimilars. Relevant clinical, regulatory, and review articles were thematically synthesized. Results: In pediatric patients with chronic conditions such as inflammatory bowel disease and rheumatologic disorders, biosimilars like infliximab and adalimumab offer efficacy and safety comparable to originator biologics, while lowering treatment costs. Economic analyses demonstrate that biosimilars are typically 15%-45% cheaper than reference products in Europe, and in some markets up to 85% lower, improving affordability and access to treatment in pediatric populations. Conclusion: Biosimilars have a great deal of promise to improve therapeutic access and lower medical expenses associated with pediatric care. However, to maximize results and guarantee therapeutic fairness in pediatric medicine, broader adoption necessitates increased age-specific clinical trials, harmonized regulations, better training for healthcare providers, and increased stakeholder trust.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.